Canagliflozin for MSI-H colorectal cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a diabetes drug, canagliflozin, for people with a specific type of colorectal cancer (MSI-H). It's for those whose cancer has continued to grow after at least two standard treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 to 80 years old.
- You have colorectal cancer that is MSI-H (a specific genetic marker), and standard treatments have stopped working or caused too many side effects.
- You have type 2 diabetes, or you do not have diabetes at all.
- Your cancer has spread or cannot be removed by surgery, and you have at least one tumor that can be measured on a scan.
- You are generally healthy enough to take part (good organ function, no severe heart or kidney problems).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding a GLP-1 receptor agonist (a drug used for diabetes and weight loss) to standard chemotherapy can help people with advanced pancreatic, colorectal, or liver cancer. It is for people who have not yet started treatment for their metastatic disease and have a BMI of 25 or higher.
This trial tests a combination of a GSL synthesis inhibitor, an immunotherapy drug, and/or regorafenib in people with a specific type of colorectal cancer (pMMR/MSS) that has not responded to at least two prior treatments. The goal is to see if this new approach can help shrink or control the cancer.
This trial tests canagliflozin, a diabetes drug, combined with immunotherapy for people with advanced solid tumors. It may help if you have type 2 diabetes or are at risk, but you don't need diabetes to join.
This trial tests whether adding the diabetes drug canagliflozin to a standard chemotherapy medicine (gemcitabine) can help treat advanced pancreatic cancer. The goal is to see if this combination can shrink tumors or improve survival.
This trial tests whether giving an immunotherapy drug (tislelizumab) together with chemotherapy before and after surgery can improve outcomes for people with a specific type of colorectal cancer (MSI-high). The goal is to see if this treatment helps shrink the tumor and reduces the risk of cancer coming back.
This trial tests a combination of two drugs, sintilimab (an immunotherapy that helps the immune system fight cancer) and gossypol acetate (a drug that may make cancer cells more vulnerable), for people with advanced colorectal cancer that has not responded to at least two prior treatments. The goal is to see if this combination can slow or stop the cancer.
Hear when a new Colorectal cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.